Contact

NEURATRIS at BIO-EUROPE SPRING 2017 (20th – 22nd March, Barcelona)

NeurATRIS is pleased to announce that we will be participating to Bio-Europe Spring (20th – 22nd March, Barcelona)

BIO-EUROPE SPRING is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in Europe's most innovative biopharma clusters.

This is a unique opportunity to learn more about NeurATRIS assets to work alongside in your translational projects in the Neuroscience field for the characterization of neurodegenerative diseases.

Do not hesitate to This email address is being protected from spambots. You need JavaScript enabled to view it. to set up a meeting.

NeurATRIS

MEASURE MULTIPLE SCLEROSIS PROGRESSION WITH A CUTTING-EDGE TECHNIQUE

Multiple sclerosis is an inflammatory disease of the nervous central system leading to a progressive destruction of the myelin sheath surrounding the axons, essential for their protection and for the transmission of the nerve impulse. Bruno Stankoff and Catherine Lubetzki’s team developed a cutting-edge imaging technique which makes possible to visualize neuron demyelination and remyelination and to quantify their degeneration. These results, published in Annals of Neurology, open the way to better treatment for patients and to the evaluation of novel remyelination therapies.

http://icm-institute.org/en/actualite/measure-multiple-sclerosis-progression-with-a-cutting-edge-technique/

 

Read more...

Thesis defense : “ Consequences of APP soluble forms overexpression in memory processes and its therapeutical application to Alzheimer’s disease.”

Wednesday September the 21st, World Alzheimer's Day, will be held at CEA of Fontenay aux roses a thesis defense by Romain Fol on this topic. The discussion will precisely focus on the “ Consequences of APP soluble forms overexpression in memory processes and its therapeutical application to Alzheimer’s disease.

Read more...

THE SILENT STAGE OF ALZHEIMER’S DISEASE

http://icm-institute.org/en/actualite/the-silent-stage-of-alzheimers-disease/

A major international conceptual diagnostic criteria and conceptual breakthrough program has been successfully launched and published, led by the UPMC and ICM researchers Professor Bruno Dubois and Professor Harald Hampel (AXA – UPMC Chair) who coordinated a distinguished group of major international key opinion leaders, based on the dynamic conceptual evolution of the paradigm of preclinical Alzheimer’s disease (AD), in the March Issue of the leading international Alzheimer Journal Alzheimer’s & Dementia, The Journal of the Alzheimer’s Association.

Read more...